Advancing the Treatment Landscape in Philadelphia-Positive ALL
Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.
Source: onclive.com